drugset / Trial / NCT01613690

Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment

NCT01613690

Phase 1 Completed 48 enrolled Novartis Pharmaceuticals
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to see how the body processes and gets rid of NVA237 in people who have impaired kidney function compared to people whose kidney function is normal.

Timeline

Start
2010-06
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycopyrrolate Small molecule 100 ug